Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
Publication|Articles|October 21, 2026
- October 2026
- Volume 92
- Issue 10
Recap: Tirzepatide Is Approved to Cut Cardiovascular Risk in Type 2 Diabetes
Fact checked by: Yasmeen Qahwash
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Advertisement
Advertisement
The FDA approved tirzepatide (Mounjaro; Eli Lilly and Company) to lower the risk of major adverse cardiovascular events (MACE)—cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke—in adults with type 2 diabetes (T2D) at high risk for these events.1
Related to this article
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Pharmacists make a difference in patients’ lives through MTM services.
Advertisement
Advertisement